Literature DB >> 17502472

Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia.

James E Galvin1, Catherine M Roe, Mary A Coats, John C Morris.   

Abstract

OBJECTIVE: To test the ability of patients to rate their own cognitive ability using the AD8 compared with informant and clinician ratings of cognitive status. DESIGN, SETTING, AND PATIENTS: The AD8 was administered to 325 consecutive participant-informant dyads enrolled in a longitudinal study at Washington University School of Medicine between April 4, 2005, and December 15, 2005. The number of AD8 items endorsed by the participant was compared with informant answers and an independently derived Clinical Dementia Rating. MAIN OUTCOME MEASURE: Strength of association was measured with Spearman (rho) and intraclass correlation coefficients. Receiver operator characteristic curves assessed the discriminative properties of the AD8.
RESULTS: The mean age of participants and informants was 72.8 years (range, 43-104 years) and 66.4 years (range, 24-101 years), respectively. The Clinical Dementia Rating was correlated with both informant (rho = 0.75, P<.001) and participant (rho = 0.34, P<.001) AD8 scores. Participants' AD8 scores had adequate agreement with informants' AD8 scores (intraclass correlation coefficient, 0.53; 95% confidence interval, 0.41-0.62) and correlated with subjective complaints of memory problems (rho = 0.47, P<.001) but not with estimates of symptom duration. The area under the receiver operator characteristic curve for the informant AD8 was 0.89 (95% confidence interval, 0.86-0.93); for the participant AD8, it was 0.78 (95% confidence interval, 0.68-0.78).
CONCLUSIONS: The AD8 is a brief measure that, when completed by an informant, differentiates nondemented from demented individuals. We now demonstrate that a self-completed AD8 also differentiates nondemented from demented individuals, although the utility was better in mildly impaired individuals compared with more demented individuals. In the absence of a reliable informant, the AD8 may be asked of the participant to gain an understanding of their perception of cognitive status.

Entities:  

Mesh:

Year:  2007        PMID: 17502472     DOI: 10.1001/archneur.64.5.725

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  54 in total

1.  Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.

Authors:  Daniel S Brown; Ira H Bernstein; Shawn M McClintock; C Munro Cullum; Richard B Dewey; Mustafa Husain; Laura H Lacritz
Journal:  Int J Geriatr Psychiatry       Date:  2015-07-14       Impact factor: 3.485

Review 2.  Cognitive assessment tools for mild cognitive impairment screening.

Authors:  Lei Zhuang; Yan Yang; Jianqun Gao
Journal:  J Neurol       Date:  2019-08-14       Impact factor: 4.849

3.  Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).

Authors:  Richard J Kryscio; Erin L Abner; Allison Caban-Holt; Mark Lovell; Phyllis Goodman; Amy K Darke; Monica Yee; John Crowley; Frederick A Schmitt
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

4.  Long-Term Impact of Caregiving and Metabolic Syndrome with Perceived Decline in Cognitive Function 8 Years Later: A Pilot Study Suggesting Important Avenues for Future Research.

Authors:  Beverly H Brummett; Shirley B Austin; Kathleen A Welsh-Bohmer; Redford B Williams; Ilene C Siegler
Journal:  Open J Med Psychol       Date:  2013-01

5.  Comparison of 2 informant questionnaire screening tools for dementia and mild cognitive impairment: AD8 and IQCODE.

Authors:  Mehrdad Razavi; Magdalena I Tolea; Jennifer Margrett; Peter Martin; Andrew Oakland; David W Tscholl; Sarah Ghods; Mazdak Mina; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Apr-Jun       Impact factor: 2.703

6.  Estimating the risk for conversion from mild cognitive impairment to Alzheimer's disease in an elderly Arab community.

Authors:  Rivka Inzelberg; Magda Massarwa; Edna Schechtman; Rosa Strugatsky; Lindsay A Farrer; Robert P Friedland
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum.

Authors:  Samantha L Allison; Thomas L Rodebaugh; Chiharu Johnston; Anne M Fagan; John C Morris; Denise Head
Journal:  Arch Clin Neuropsychol       Date:  2019-10-24       Impact factor: 2.813

8.  Event perception: Translations and applications.

Authors:  Lauren L Richmond; David A Gold; Jeffrey M Zacks
Journal:  J Appl Res Mem Cogn       Date:  2017-06

9.  Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression.

Authors:  Richard B Dewey; Aanchal Taneja; Shawn M McClintock; C Munro Cullum; Richard B Dewey; Ira Bernstein; Mustafa M Husain
Journal:  Cogn Behav Neurol       Date:  2012-09       Impact factor: 1.600

10.  The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.

Authors:  Edgar Turner Overton; Tej D Azad; Neva Parker; Debra Demarco Shaw; Judy Frain; Teresa Spitz; Elizabeth Westerhaus; Robert Paul; David B Clifford; Beau M Ances
Journal:  J Neurovirol       Date:  2013-01-24       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.